Market Intelligence, Clinical Progress, and High-Purity Reagents for Cell Cycle Regulation and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CDK4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDK4 Recombinant Protein (Wild-type & Mutant) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CDK4 Products |
| Gene Delivery | CDK4 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction (overexpression/rescue models). |
View CDK4 Products |
| Benchmark Ab | Anti-CDK4 Recombinant Antibody (Research Grade) Sequence Verified. For Western Blot, IP, and cellular validation. (Clone: DCS-35 equivalent). |
View CDK4 Products |
| Validator | CDK4 siRNA Set For knockdown verification and specificity controls. |
View CDK4 Products |
| Related Target: CDK6 | CDK6 Recombinant Protein Essential for selectivity counter-screening (CDK4 vs CDK6 discrimination). |
View CDK6 Products |
| Related Target: CCND1 | Cyclin D1 (CCND1) Recombinant Protein Essential activator for functional CDK4/Cyclin D1 holoenzyme assays. |
View CCND1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CDK4 vs CDK6 vs CDK2 Selectivity (Hematology-sparing differentiation) | High-purity (>95%) CDK4, CDK6, and CDK2 recombinant kinase domain proteins for parallel IC50 determination and selectivity indexing. |
| Resistance Mutation Analysis (Acquired kinase domain mutations, e.g., CMM3-associated) | CDK4 Wild-Type & Mutant Recombinant Proteins (including activation loop variants); HEK293 expressed, sequence verified for binding and kinetic studies. |
| Holoenzyme Complex Assembly (CDK4/Cyclin D1 functional reconstitution) | High-purity CCND1 (Cyclin D1) protein available separately for reconstituting active CDK4/Cyclin D1 complexes. |
| False Positives & Lack of Controls | Validated CDK4 siRNA included for target-specificity confirmation in cellular assays; research-grade antibody for orthogonal validation. |
Live CDK4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CDK4/6 inhibitor market has matured with three approved agents (Palbociclib, Ribociclib, Abemaciclib), dominating HR+/HER2- breast cancer. However, the field is pivoting toward next-generation CDK4-selective inhibitors (sparing CDK6 to mitigate neutropenia), PROTAC degraders, and novel indications such as glioblastoma (where blood-brain barrier penetration is critical). The next wave of R&D focuses on overcoming acquired resistance through combination with PI3K/mTOR pathways and SERDs, and exploring CDK4 as a synthetic lethal target in specific genetic contexts. Rare activating mutations in CDK4 (e.g., CMM3-associated variants R24C, R24H) generate dominant oncogenes that require specialized resistant mutant proteins for inhibitor development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (including next-gen selective) | Pfizer, Novartis, Eli Lilly | HR+/HER2- Breast Cancer, Glioblastoma | Selectivity Assay (need high-purity CDK4 vs CDK6 vs CDK2 proteins) |
| PROTACs/Degraders | Arvinas, C4 Therapeutics, Kymera | Refractory Solid Tumors | Ternary Complex Formation (need active CDK4 complexes + E3 ligase components) |
| Combination Therapy (CDK4i + PI3K/mTORi or SERD) | AstraZeneca, Relay Therapeutics | Resistant Breast Cancer, Solid Tumors | Pathway Profiling and mutant vs WT protein comparison |
| RNA Interference | Alnylam (early stage) | Oncology | Knockdown Efficiency (need validated CDK4 siRNA controls) |